Compare ARK Next Generation Internet ETF (ARKW) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Next Generation Internet ETF vs Inovio Pharmaceuticals Inc — how do they compare? ARK Next Generation Internet ETF trades at $147, while Inovio Pharmaceuticals Inc trades at $1.2 (market cap $97.91M). The key difference: ARK Next Generation Internet ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ARKW | INO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $2.87 |
52-Week Low | $114.45 | $1.05 |
Market Cap | — | $97.91M |
Enterprise Value | — | $68.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $148.42, down 0.75% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 52.51 suggesting balanced buying pressure. Support levels are established at $144 and $142, while resistance sits at $147 and $148. Recent news highlights Cathie Wood's continued focus on innovative technology investments through her ETF strategies.
The ETF's exposure to disruptive innovation themes presents growth potential amid technology sector momentum. Key risks include concentration in high-growth tech stocks and market volatility sensitivity. Institutional interest remains strong given ARK Invest's track record in identifying transformative technologies.
INO trades at $1.18, down 0.84% with bearish technical signals. The company shows minimal revenue of $65K against massive losses, with a net margin of -130,000% and negative cash flow. Recent news highlights an active FDA review for INO-3107 with an October 2026 decision date, while multiple law firms investigate potential fiduciary breaches by directors.
The investment case hinges on the binary FDA approval of INO-3107. While analyst consensus is 53% buy-rated, fundamental metrics are deeply negative. Key risks include clinical trial outcomes, cash burn, and legal scrutiny. Upside depends entirely on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Next Generation Internet ETF
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
